Molecule Details
| InChIKey | YFIZRWPXUYFCSN-UHFFFAOYSA-N |
|---|---|
| Canonical SMILES | CCCc1c(OCCCOc2cc(O)c(-c3ccc(F)cc3)cc2CC)cccc1Oc1ccccc1C(=O)O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.97 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12850 |
|---|---|
| Drug Name | Etalocib |
| CAS Number | 161172-51-6 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Etalocib has been used in trials studying the treatment of Pancreatic Cancer, Carcinoma, Non-Small-Cell Lung, and Unspecified Adult Solid Tumor, Protocol Specific. |
Categories: Acids, Carbocyclic Benzene Derivatives
Cross-references: BindingDB: 50029450 CHEMBL329123 ChemSpider: 154905 PubChem:177941 PubChem:347829010 Wikipedia: Etalocib ZINC: ZINC000003930629
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| Q15722 | LTB4R | Leukotriene B4 receptor 1 | antagonist | targets |